J&J faces federal probe over alleged relationships with PBMs


Johnson & Johnson ($JNJ) is facing a federal probe over its relationships with pharmacy benefit managers. The demand for documents is the latest Department of Justice move to investigate a drugmaker under the False Claims Act.

The U.S. Attorney’s office sent J&J’s Janssen Pharmaceuticals unit a civil investigative demand for information about its contractual relationships with PBMs. The demand covers Jan. 1, 2006 to the present and "certain pharma products." It was issued in connection with an investigation under the False Claims Act, the company disclosed in its quarterly filing with the Securities and Exchange Commission.

J&J is staying quiet about the probe. "The statement in the filing is accurate, and we are cooperating fully in the process," the company told FiercePharma in an email. "We have nothing further to add at this point."


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

J&J is not the only company dealing with federal probes. Pharma peers including Valeant ($VRX) and Horizon Pharma ($HZNP) have also come under fire during the past year from lawmakers, and across the pharma industry, companies have agreed to pay fines and penalties to settle FCA and kickbacks allegations.

The demand for information about relationships with PBMs appears to be unusual, however. If the Justice Department chooses to zero in on pharma's contracts with those companies, which negotiate prices and set reimbursement conditions, other drugmakers could find themselves roped in.

In October, Valeant revealed that it got subpoenas from the U.S. Attorney’s office for the Southern District of New York and the U.S. Attorney’s office for the District of Massachusetts for documents about its financial support to patients, drug distribution and pricing decisions. The same month, the company cut ties with specialty pharma Philidor amid rumors that the pharmacy changed doctors’ orders to get more money from insurers.

Horizon has also encountered federal pushback. In March, the company said that the U.S. Attorney’s Office for the Southern District of New York was investigating its financial support to patients and its alleged ties to specialty pharmacies.

- read the J&J filing

Related Articles:
J&J's Invokana under scrutiny in EU for potential link to toe amputations
Horizon Pharma joins Valeant in DOJ's specialty pharmacy probe
Defensive Valeant sets up board committee to probe fraud allegations
Valeant's SEC probe? A backfire from its request that the agency investigate short-seller foe: Reuters
Another snafu for Valeant as internal probe triggers restated earnings


Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.